Physician profile
Abdallah Bitar
NPI 1033485115
$26,817.06
in general payments reported to CMS, 2019-2025
31 companies · $3,703 in 2025
The $3,703 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,132 · 2020: $1,150 · 2021: $1,411 · 2022: $7,289 · 2023: $5,879 · 2024: $3,253 · 2025: $3,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $7,000 · Consulting Fee: $2,500 · Food and Beverage: $1,958 · Travel and Lodging: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $7,000.00 |
| Consulting Fee | $2,500.00 |
| Food and Beverage | $1,957.81 |
| Travel and Lodging | $1,377.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Asahi Intecc USA, INC. | $17,612.06 | 2021-2025 | Peripheral Vascular, Asahi Corsair Pro Microcatheter Xs, Asahi Peripheral Vascular Wires |
| Abbott Laboratories | $2,578.07 | 2019-2024 | Coroflow, Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $1,792.01 | 2019-2025 | Avvigo Guidance System |
| Edwards Lifesciences Corporation | $1,252.89 | 2019 | |
| Abiomed | $760.17 | 2022-2025 | Impella |
| Philips North America LLC | $355.06 | 2021-2023 | |
| Medtronic, INC. | $327.94 | 2021-2025 | Resolute Onyx |
| Astrazeneca Pharmaceuticals LP | $322.75 | 2020-2022 | |
| Medtronic Vascular, INC. | $316.96 | 2019-2020 | |
| Livanova USA, INC. | $274.19 | 2019-2022 | |
| Inari Medical, INC. | $167.25 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.52 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $102.23 | 2019-2023 | |
| Terumo Medical Corporation | $101.24 | 2021 | |
| Amgen INC. | $100.97 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.49 | 2019-2020 | |
| Getinge USA Sales, LLC | $60.85 | 2024 | Cardiohelp |
| Amarin Pharma, INC. | $57.29 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $56.98 | 2020-2021 | |
| Cvrx, INC. | $48.40 | 2023 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $47.54 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $39.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $37.14 | 2021 | |
| Chiesi USA, INC. | $35.79 | 2020 | |
| Shockwave Medical, INC | $25.20 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Otsuka America Pharmaceutical, INC. | $22.05 | 2019 | |
| Pfizer INC. | $21.71 | 2024 | |
| Teleflex LLC | $19.63 | 2019 | |
| Merck Sharp & Dohme LLC | $15.04 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.25 | 2020 | |
| Cardiovascular Systems INC. | $7.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdallah Bitar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.